SAUDI ARABIA – The Saudi Gastroenterology Association (SGA) has joined forced with Takeda Pharmaceutical Company Limited with an aim to advance inflammatory bowel disease (IBD) care in the Kingdom of Saudi Arabia.
Under the strategic deal, the two parties will work together to raise IBD awareness as well as to advance knowledge and capabilities across Saudi Arabia’s healthcare sector in a bid to reduce the burden of the debilitating condition on society.
“Takeda and SGA will pool their collective resources, expertise, and knowledge to enhance IBD treatment by providing education, training, and knowledge-sharing platforms so that healthcare practitioners and facilities are better equipped to support patient needs,” SGA informed in a release.
The partnership will focus on strategic healthcare areas including identifying how existing healthcare resources can be better optimized for IBD treatment, establishing modern diagnosis methods, supporting education, and expanding patients’ access to treatment.
SGA Chairman Prof. Majid AlMadi signed the agreement on behalf of the institution while Khaled Sary who is the Country Head, Kingdom of Saudi Arabia at Takeda signed on behalf of the biopharmaceutical leader on the sidelines of the annual SGA Congress held in Jeddah.
Commenting on the agreement, Prof. Majid AlMadi noted: “With the growing popularity of fast-food and high-stress levels, the incidence rate of IBD in Saudi is rising across all age groups. A heavy burden not only on patients but society in general, IBD imposes significant costs to our healthcare sector.”
He highlighted that the partnership with Takeda will support ongoing efforts to improve understanding of IBD symptoms as well as enhance diagnosis and treatment plans that will ensure patients can better manage their symptoms and lead a normal life.
“As Saudi Arabia undertakes one of the largest transformation efforts of its health sector to deliver a system that ensures access, quality, and value, we are working to ensure IBD care remains at the top of the agenda.” the SGA Chairman reaffirmed his commitment to the Saudi Arabian people.
Meanwhile, Country Head Khaled Sary emphasized that besides ongoing efforts to develop cutting-edge treatments for patients across Takeda’s gastroenterology portfolio, they believe in the vital importance of partnerships in positively impacting patients’ lives.
“Continuing a legacy of six years of collaboration, our latest agreement with SGA will see us provide critical resources, knowledge, and tools to enhance awareness, diagnosis and IBD treatment protocols so that patients are fully supported on their journey to better health.” he added.